Posted by Michael Wonder on 20 Jul 2020
Many drug companies working on COVID-19 vaccines and treatments are lobbying harder than usual
20 July 2020 - Pharmaceutical companies racing to develop coronavirus treatments and vaccines have upped their lobbying presence in the past three months, as drug companies work to combat the pandemic and fend off many lawmakers’ long-standing quest to lower drug prices via regulation.
Takeda, which is working to produce a plasma treatment for COVID-19, more than doubled its lobbying expenditure in the second quarter of 2020 compared to the same period a year ago: from $570,000 to $1.33 million.
